AssetMark’s Dyne Therapeutics DYN Stock Holding History
Bought
Maintained
Sold
Other funds holding DYN
SL
AssetMark's DYN Position: Q3 2026 in Review
AssetMark increased its Dyne Therapeutics (DYN) stake by 70% in Q3 2026, buying an estimated $461K and bringing the position to 48,702 shares worth $785K. The position accounts for ﹤0.01% of the portfolio, ranked #1146.
AssetMark first reported a position in DYN in Q1 2026 and has held it in 3 quarters since. 179 funds tracked by Wall St. Rank hold DYN as of Q3 2026.
- AssetMark held 48,702 shares of Dyne Therapeutics worth $785K as of Q3 2026.
- AssetMark bought 20,081 Dyne Therapeutics shares in Q3 2026, an estimated $461K.
- Dyne Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1146 holding.
- AssetMark first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 179 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.